l General Information |
Product Name | Conivaptan HCl |
General description | Conivaptan HCl is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia. |
Synonym | N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; hydrochloride |
Purity | ≥98.0%(HPLC) | CAS Number | 168626-94-6 |
Formula | C32H27ClN4O2 | Molecular Weight | 535.044 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to Beige Powder |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | ~5mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Conivaptan hydrochloride is the hydrochloride salt of conivaptan. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2, and is used for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). It has a role as a vasopressin receptor antagonist. It contains a conivaptan. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
